Related Experiment Video

Updated: Jul 20, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors

M A Alaoui-Jamali1

  • 1Segal comprehensive cancer center, McGill university, Montreal, Canada. moulay.alaoui-jamali@mcgill.ca

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|September 5, 2006
PubMed

Insights

Tyrosine kinases are key in cancer, and targeted therapies show promise. However, drug resistance mechanisms, like mutations and signaling changes, limit treatment effectiveness.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Protein kinases, particularly tyrosine kinases, are crucial in cancer development.
  • Targeted therapies inhibiting tyrosine kinase signaling have shown clinical success.
  • Resistance to these targeted therapies is a significant clinical challenge.

Purpose of the Study:

  • To provide an overview of tyrosine kinase signaling diversity.
  • To discuss the impact of tyrosine kinase signaling on cancer cell response to targeted inhibitors.
  • To highlight mechanisms of resistance to tyrosine kinase inhibitors.

Main Methods:

  • Literature review of tyrosine kinase signaling pathways.
  • Analysis of clinical trial data for targeted tyrosine kinase inhibitors.
  • Review of experimental models investigating resistance mechanisms.

Main Results:

  • Tyrosine kinases play a central role in various cancers.
  • Targeted therapies have demonstrated significant clinical utility.
  • Mechanisms of resistance, including target heterogeneity, mutations, and compensatory signaling, reduce therapeutic efficacy.

Conclusions:

  • Tyrosine kinases are vital therapeutic targets in oncology.
  • Understanding resistance mechanisms is crucial for improving targeted therapy efficacy.
  • Further research into tyrosine kinase signaling and resistance is needed for better cancer treatment.

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...